Were the Genprex (GNPX) insider sales by Brent M. Longnecker related to taxes?

Yes. A footnote in the Form 4 states the reported shares were sold on April 14, 2026 for tax purposes. This indicates the transactions were primarily to satisfy tax obligations rather than a large discretionary portfolio decision.

Genprex director sells small block of shares

Genprex, Inc. director Brent M. Longnecker reported small open-market sales of Genprex common stock, primarily for tax purposes.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Genprex, Inc. director Brent M. Longnecker reported small open-market sales of Genprex common stock, primarily for tax purposes. On April 14, 2026, he sold 8 shares of common stock at $1.23 per share from his direct holdings and 10 shares at $1.23 per share through indirect ownership by Longnecker Associates Ltd. Following these transactions, he directly holds 9,157 shares of Genprex common stock, with no remaining indirect shares reported in this filing.

Insider Trade Summary

Net Seller: 18 shares

Net Sell 2 txns

Insider LONGNECKER BRENT M

Role Director

Sold 18 shs ($22.14)

Type	Security	Shares	Price	Value
Sale	Common Stock	8	$1.23	$9.84
Sale	Common Stock	10	$1.23	$12.30

Holdings After Transaction: Common Stock — 9,157 shares (Direct); Common Stock — 0 shares (Indirect, By: Longnecker Associates Ltd)

Footnotes (1)

F1. Represents shares sold by the Reporting Person on April 14, 2026 for tax purposes.

Key Figures

Direct shares sold: 8 shares Indirect shares sold: 10 shares Sale price: $1.23 per share +2 more

5 metrics

Direct shares sold 8 shares Common Stock sold April 14, 2026 at $1.23

Indirect shares sold 10 shares Common Stock via Longnecker Associates Ltd at $1.23

Sale price $1.23 per share Open-market transactions on April 14, 2026

Direct holdings after sale 9,157 shares Genprex common stock directly owned post-transaction

Total shares sold 18 shares Net shares sold across two transactions

Key Terms

open-market sale, indirect ownership, Common Stock, for tax purposes

4 terms

open-market sale financial

"transaction_action: "open-market sale" for both common stock transactions"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

"ownership_code "I" with nature_of_ownership "By: Longnecker Associates Ltd""

Common Stock financial

"security_title: "Common Stock" for each reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

for tax purposes financial

"footnote: "Represents shares sold by the Reporting Person on April 14, 2026 for tax purposes.""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Genprex (GNPX) disclose for Brent M. Longnecker?

Genprex director Brent M. Longnecker disclosed two small open-market sales of common stock. On April 14, 2026, he sold 8 directly held shares and 10 indirectly held shares, each at $1.23 per share, mainly for tax purposes according to the filing footnote.

How many Genprex (GNPX) shares did Brent M. Longnecker sell and at what price?

He sold a total of 18 Genprex common shares. This included 8 directly held shares and 10 indirectly held shares, all sold on April 14, 2026, at a reported price of $1.23 per share in open-market transactions.

How many Genprex (GNPX) shares does Brent M. Longnecker hold after these transactions?

After the reported sales, Brent M. Longnecker holds 9,157 Genprex common shares directly. The Form 4 shows zero remaining indirectly held shares through Longnecker Associates Ltd. No derivative securities are listed as remaining positions in this particular filing.

What is the nature of Brent M. Longnecker’s indirect Genprex (GNPX) holdings?

The filing identifies 10 sold shares as indirectly owned "By: Longnecker Associates Ltd." After this sale, the indirect position shown is zero shares. The remaining reported ownership is entirely direct, totaling 9,157 Genprex common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/15/2026 - 06:50 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LONGNECKER BRENT M

(Last)

(First)

(Middle)

3300 BEE CAVE ROAD

#650-227

(Street)

AUSTIN

TEXAS

78746

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Genprex, Inc. [ GNPX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/14/2026		S		8⁽¹⁾	D	$1.23	9,157	D
Common Stock	04/14/2026		S		10⁽¹⁾	D	$1.23	0	I	By: Longnecker Associates Ltd

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares sold by the Reporting Person on April 14, 2026 for tax purposes.

	/s/ Brent Longnecker	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR